Skip to main content
. 2024 Aug 30;38(11):6356–6367. doi: 10.1007/s00464-024-11220-z

Table 1.

Comparison of the demographic and clinical characteristics of patients before and after PSM

Variables Before PSM After PSM
Total (n = 2,214) ET group (n = 1,417) SR group (n = 797) P-value ET group (n = 698) SR group (n = 698) P-value
Age, years  < 0.001 1.000
 < 80 2,007 (90.7%) 1,326 (93.6%) 681 (85.4%) 643 (92.1%) 643 (92.1%)
 ≥ 80 207 (9.3%) 91 (6.4%) 116 (14.6%) 55 (7.9%) 55 (7.9%)
Sex 0.226 0.830
Male 1,024 (46.3%) 669 (47.2%) 355 (44.5%) 330 (47.3%) 326 (46.7%)
Female 1,190 (53.7%) 748 (52.8%) 442 (55.5%) 368 (52.7%) 372 (53.3%)
Year of diagnosis  < 0.001 0.921
2000–2006 223 (10.1%) 164 (11.6%) 59 (7.4%) 48 (6.9%) 51 (7.3%)
2007–2013 683 (30.8%) 555 (39.2%) 128 (16.1%) 111 (15.9%) 114 (16.3%)
2014–2020 1,308 (59.1%) 698 (49.3%) 610 (76.5%) 539 (77.2%) 533 (76.4%)
Grade  < 0.001 1.000
I 1,838 (83.0%) 1,124 (79.3%) 714 (89.6%) 624 (89.4%) 624 (89.4%)
II 376 (17.0%) 293 (20.7%) 83 (10.4%) 74 (10.6%) 74 (10.6%)
T stage  < 0.001 0.772
T1 2,126 (96.0%) 1,377 (97.2%) 749 (94.0%) 684 (98.0%) 680 (97.4%)
T2 45 (2.0%) 30 (2.1%) 15 (1.9%) 10 (1.4%) 13 (1.9%)
T3 43 (1.9%) 10 (0.7%) 33 (4.1%) 4 (0.6%) 5 (0.7%)
Marital status 0.534 0.956
Married 1,322 (59.7%) 853 (60.2%) 469 (58.8%) 419 (60.0%) 420 (60.2%)
Unmarried 892 (40.3%) 564 (39.8%) 328 (41.2%) 279 (40.0%) 278 (39.8%)
Chemotherapy  < 0.001 0.526
No/Unknown 2,191 (99.0%) 1,413 (99.7%) 778 (97.6%) 694 (99.4%) 692 (99.1%)
Yes 23 (1.0%) 4 (0.3%) 19 (2.4%) 4 (0.6%) 6 (0.9%)
Survival months, median (IQR) 54.0(23.0,97.0) 67.0(33.0,112.5) 34.0(11.0,63.0)  < 0.001 40.0(20.0,67.0) 36.5(12.0,63.3) 0.002

ET endoscopic therapy, SR surgical resection, PSM propensity score matching, IQR interquartile range

Bold values indicate P < 0.05